AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A2: In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis

Journal of Pharmacology and Experimental Therapeutics - United States
doi 10.1124/jpet.118.255034
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Related search

Selective Deletion of Group v Phospholipase A2 in Macrophages Reduces Alternaria-Induced Pulmonary Inflammation

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Correction to “Highly Potent 2-Oxoester Inhibitors of Cytosolic Phospholipase A2 (GIVA cPLA2)”

ACS Omega
ChemistryChemical Engineering
2019English

HIV-1 and Alcohol Abuse Promote Astrocyte Inflammation: A Mechanistic Synergy via the Cytosolic Phospholipase A2 Pathway

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2015English

Molecular Characterization of Cytosolic Phospholipase A2-Β

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1999English

Cytosolic Phospholipase A2 Modulates TLR2 Signaling in Synoviocytes

PLoS ONE
Multidisciplinary
2015English

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and in Vivo Characterization

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

The First Potent Inhibitor of Mammalian Group X Secreted Phospholipase A2: Elucidation of Sites for Enhanced Binding

English

Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and StructureActivity Relationships

English

Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and StructureActivity Relationships

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy